Global Immunoglobulins Market 2023

September 2023 | 88 pages | ID: GA2D44287773EN
Gen Consulting Company

Abstracts

The Immunoglobulins Market is projected to reach USD 24.29 billion by 2029, with a 6.3% CAGR from 2023 to 2029. Immunoglobulins are glycoprotein molecules produced by plasma cells in response to antigens. The pandemic has impacted the plasma derivatives industry, increasing costs despite lower volumes collected. However, advancements in immunoglobulin products for rare and autoimmune diseases have fueled market growth. Technological developments in plasma fractionation and partnerships with plasma collection agencies are driving the market.

The report covers market size and growth, segmentation, competitive landscape, trends and strategies for global immunoglobulins market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.

Market Segmentation
The market is segmented based on various factors, including product, application, end-user, and geography.
Product: intramuscular immunoglobulin (IMIg), intravenous immunoglobulin (IVIg), subcutaneous immunoglobulin (SCIg)
Application: primary immunodeficiency, chronic immune deficiency polyradiculoneuropathy, secondary immunodeficiency, immune thrombocytopenic purpura, myasthenia gravis, others
End user: hospitals and clinics, homecare

Segmentation by Geography
North America – US, Canada
Europe – Germany, France, UK, Italy, Spain
APAC - China, Japan, India, South Korea, Australia
Latin America – Brazil, Mexico, Argentina
Middle East & Africa – South Africa, Saudi Arabia, Turkey

IVIg is commonly used in the management of autoimmune diseases and immunodeficiency. It involves administering immunoglobulins intravenously for maximum bioavailability and efficacy. Primary immunodeficiency is the leading segment, accounting for 26.3% of the global immunoglobulins market in 2022. Symptoms of primary immunodeficiencies include recurring infections, inflammation, and low platelet count. Hospitals and clinics are the largest end-users in the market, but home care is expected to grow rapidly due to the rising demand for home healthcare services.

North America accounted for 46.4% of the global immunoglobulins market in 2022, supported by factors such as increased personal health awareness, patient-centric healthcare, advanced infrastructure, a robust plasma collection network, and prominent global vendors. Europe is the second-largest market, driven by high demand and a well-regulated market with a focus on safe blood and plasma collection. The Asia-Pacific (APAC) region is an emerging market, particularly for autoimmune disorder treatments. China leads the APAC market due to its population's high awareness of blood donation and its importance in manufacturing life-saving products.

Competitive Landscape
The industry is dominated by CSL Limited, Takeda Pharmaceutical Company Limited, and Grifols S.A. These vendors face intense competition and strive to gain an advantage through new product introductions and regulatory approvals. Emerging markets and low-resource countries offer opportunities for new entrants due to larger populations and willingness to donate blood or plasma. Plasma procurement is crucial for vendors, leading to the establishment of extensive collection networks. Partnerships with official plasma collection agencies have driven growth for many vendors. Key companies profiled include ADMA Biologics Inc., Bharat Serums And Vaccines Limited (BSV), Biotest AG, China Biologic Products, Inc. (Shandong Taibang Biological Products Co., Ltd.), CSL Limited, Grifols, S.A., Johnson & Johnson, Kedrion Biopharma Inc. (Kedrion SpA), LFB S.A., Octapharma AG, Reliance Life Sciences Pvt. Ltd., Shanghai RAAS Blood Products Co., Ltd., Takeda Pharmaceutical Company Limited, and Zydus Lifesciences Limited.

Scope of the Report
To analyze and forecast the market size of the global immunoglobulins market.
To classify and forecast the global immunoglobulins market based on product, application, end user, geography.
To identify drivers and challenges for the global immunoglobulins market.
To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global immunoglobulins market.
To identify and analyze the profile of leading players operating in the global immunoglobulins market.

Why Choose This Report
Gain a reliable outlook of the global immunoglobulins market forecasts from 2023 to 2029 across scenarios.
Identify growth segments for investment.
Stay ahead of competitors through company profiles and market data.
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

1.1 Description
1.2 Objectives of The Study
1.3 Market Segment
1.4 Years Considered for The Report
1.5 Currency
1.6 Key Target Audience

PART 2. RESEARCH METHODOLOGY

2.1 Primary Research
2.2 Secondary Research

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

4.1 Introduction
4.2 Drivers
4.3 Restraints

PART 5. GLOBAL IMMUNOGLOBULINS MARKET BY PRODUCT

5.1 Intramuscular immunoglobulin (IMIg)
5.2 Intravenous immunoglobulin (IVIg)
5.3 Subcutaneous immunoglobulin (SCIg)

PART 6. GLOBAL IMMUNOGLOBULINS MARKET BY APPLICATION

6.1 Primary immunodeficiency
6.2 Chronic immune deficiency polyradiculoneuropathy
6.3 Secondary immunodeficiency
6.4 Immune thrombocytopenic purpura
6.5 Myasthenia gravis
6.6 Others

PART 7. GLOBAL IMMUNOGLOBULINS MARKET BY END USER

7.1 Hospitals and clinics
7.2 Homecare

PART 8. GLOBAL IMMUNOGLOBULINS MARKET BY GEOGRAPHY

8.1 North America
8.2 Europe
8.3 APAC
8.4 Latin America
8.5 Middle East & Africa

PART 9. COMPANY PROFILES

9.1 ADMA Biologics Inc.
9.2 Bharat Serums And Vaccines Limited (BSV)
9.3 Biotest AG
9.4 China Biologic Products, Inc. (Shandong Taibang Biological Products Co., Ltd.)
9.5 CSL Limited
9.6 Grifols, S.A.
9.7 Johnson & Johnson
9.8 Kedrion Biopharma Inc. (Kedrion SpA)
9.9 LFB S.A.
9.10 Octapharma AG
9.11 Reliance Life Sciences Pvt. Ltd.
9.12 Shanghai RAAS Blood Products Co., Ltd.
9.13 Takeda Pharmaceutical Company Limited
9.14 Zydus Lifesciences Limited
DISCLAIMER